Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC therapy in renovascular hypertension
NCT02266394Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Oct 2014
- Primary completion
- Sep 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of mesenchymal stem cells in renovascular hypertension (RVH), atherosclerotic renal artery stenosis (ARAS), ischemic nephropathy and 1 more (2 arms), sponsored by Mayo Clinic. Primary endpoints: Change in Kidney function at 3 months and Safety of Mesenchymal stem cell infusion at 2 years. Started Oct 2014; status: completed.
02
Drugs
mesenchymal stem cells
03
Conditions
renovascular hypertension (RVH)atherosclerotic renal artery stenosis (ARAS)ischemic nephropathychronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT02266394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02266394.